Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-450/r + ABT-530 +/- RBV in HCV Genotype 3
NCT02068222Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2014
- Primary completion
- Mar 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of paritaprevir, pibrentasvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Apr 2014; status: completed.
02
Drugs
paritaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02068222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068222.